FDA clears Synchron's brain-computer interface device for human trials

A company that makes an implantable brain-computer interface (BCI) has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.”

Synchron received the FDA’s green light ahead of competitors like Elon Musk’s Neuralink. Before such companies can sell BCIs commercially in the US, they need to prove that the devices work and are safe. The FDA will provide guidance for trials

→ Continue reading at Engadget

Similar Articles


Most Popular

Port Angeles High School parents asked to pick up students after bomb threat

A bomb threat prompted the Port Angeles School District to close the high school campus Tuesday while police investigate. PORT ANGELES, Wash. —...

A comprehensive breakdown of the Epic v. Apple ruling

On Friday, a California judge ruled on the influential Epic v....

Debbie Allen Reflects on Storied Career, Being the First Black Female Recipient of the Governors Award

When Debbie Allen received a call from Television Academy chairman and CEO Frank Scherma saying she’d been selected to receive the 2021 Governors Award,...